As medical professionals, we continually strive to understand the intricacies of diseases that affect the human body. One such condition is Parkinson's disease (PD), a neurodegenerative disorder with a multifaceted etiology and presentation.
PD is primarily characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta. This loss leads to decreased striatal dopamine levels, disrupting the balance between the direct and indirect pathways of the basal ganglia, resulting in motor symptoms.
The cardinal symptoms of PD include bradykinesia, resting tremor, rigidity, and postural instability. However, non-motor symptoms such as autonomic dysfunction, cognitive impairment, and mood disorders are also prevalent and significantly impact patients' quality of life.
PD diagnosis is primarily clinical, based on the presence of characteristic motor symptoms. Neuroimaging techniques like DAT-SPECT can support the diagnosis but are not routinely used due to their high cost and limited availability. There are no specific biomarkers for PD, making early diagnosis challenging.
Treatment of PD is symptomatic, with levodopa being the most effective medication for motor symptoms. However, its long-term use is associated with motor complications. Other treatment options include dopamine agonists, MAO-B inhibitors, and deep brain stimulation for refractory cases.
Current research efforts are focused on understanding the genetic and environmental factors contributing to PD's pathogenesis, identifying reliable biomarkers for early diagnosis, and developing disease-modifying therapies.
PD is a complex disorder with a significant impact on patients' lives. As medical professionals, we must stay abreast of the latest research to provide the best care for our patients and contribute to the ongoing efforts to unravel the mysteries of this disease.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation